Triazavirin Uses, Dosage, Side Effects and more
Triazavirin is a guanine nucleotide analog antiviral originally developed in Russia that has shown efficacy against influenza A and B, including the H5N1 strain. It appears that Triazavirin has shown promise in reducing influenza disease severity and associated complications. Given the similarities between SARS-CoV-2 and H5N1, health officials are investigating Triazavirin as an option to combat SARS-CoV-2, the coronavirus responsible for COVID-19.
| Trade Name | Triazavirin |
| Generic | Triazavirin |
| Triazavirin Other Names | Riamilovir, Triazavirin |
| Type | |
| Formula | C5H4N6O3S |
| Weight | Average: 228.19 Monoisotopic: 228.006559187 |
| Protein binding | Data regarding the protein binding of triazavirin is not readily available. |
| Groups | Experimental |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Triazavirin is an antiviral used to treat several strains of influenza.
Triazavirin was developed in Russia as a potential treatment of Influenza A and B infections.
How Triazavirin works
Triazavirin is a guanosine nucleotide analog that inhibits RNA synthesis.
Toxicity
The intraperitoneal LD50 of triazavirin in mice is 1400±120mg/kg in mice and the intragastric LD50 is 2200±96mg/kg.
Patients experiencing an overdose may present with nausea, vomiting, dyspepsia, and stomach pain. Treat overdose with symptomatic and supportive treatment, which may include discontinuation of treatment.
Food Interaction
- Take with or without food.
Volume of Distribution
In rabbits, intragastric triazavirin has a volume of distribution of 83.5±19.2L/kg while intravenous triazavirin has a volume of distribution of 1.2±0.3L/kg.
Elimination Route
In rabbits, intragastric triazavirin reaches a Cmax of 1.1±0.1mg/L, with a Tmax of 0.40±0.16h, and an AUC of 3.10±0.8mg*h/L. In rabbits, intravenous triazavirin has an AUC of 1.2±0.3mg*h/L.
In humans, triazavirin reaches a Cmax of 4.8µg/mL, with a Tmax of 1-1.5h, and an AUC of 12.8µgµg/h*mL.
Half Life
In rabbits, intragastric triazavirin has a half life of 1.1±0.1h while intravenous triazavirin has a half life of 0.50±0.09h.
The half life of triazavirin is 1-1.5h.
Clearance
In rabbits, intragastric triazavirin has a clearance of 37.0±11.2L/h*kg while intravenous triazavirin has a clearance of 14.0±3.7L/h*kg.
The clearance of triazavirin is 246mL/min.
Elimination Route
Data regarding the route of elimination of triazavirin is not readily available.
